Advertisement

Tumor Biology

, Volume 37, Issue 4, pp 4293–4294 | Cite as

A premature proposal for new liver cancer seromarkers

  • Liu-Cheng Wu
  • Wen-Feng Gong
  • Jian-Hong Zhong
Commentary

Optimal treatment of liver cancer depends on correctly determining whether tumors are primary hepatocellular carcinoma (HCC) or secondary carcinoma that metastasized from an extrahepatic source. Nearly all cancers that originate outside the liver can metastasize to that organ, raising the risk of misdiagnosis and suboptimal treatment. Indeed, the incidence of HCC in China is similar to that of metastatic liver carcinoma. While pathology provides the best method for differentiating primary and secondary cancer, it is rarely used preoperatively to diagnose liver cancer.

Instead, a combination of imaging and seromarker analysis, particularly of alpha-fetoprotein (AFP), is performed. Despite extensive studies analyzing the usefulness of AFP for diagnosing HCC [1], monitoring patients with cirrhosis for emergence of HCC [2] or detecting HCC recurrence after surgery [3, 4], its clinical value remains controversial. This is in part because sensitivity and specificity can vary widely,...

Keywords

Liver Cancer Sialic Acid Leucine Aminopeptidase Liver Carcinoma Primary Hepatocellular Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgement

This study was supported by projects from the Self-raised Scientific Research Fund of the Ministry of Health of Guangxi Province (nos. Z2015716, Z2015601, Z2015621, Z2014241).

Conflicts of interests

The authors declare that they have no conflicts of interest concerning this article.

References

  1. 1.
    Colli A, Fraquelli M, Casazza G, et al. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol. 2006;101(3):513–23.CrossRefPubMedGoogle Scholar
  2. 2.
    Chang TS, Wu YC, Tung SY, et al. Alpha-fetoprotein measurement benefits hepatocellular carcinoma surveillance in patients with cirrhosis. Am J Gastroenterol. 2015;110(6):836–44. quiz 845.CrossRefPubMedGoogle Scholar
  3. 3.
    Siripongsakun S, Wei SH, Lin S, et al. Evaluation of alpha-fetoprotein in detecting hepatocellular carcinoma recurrence after radiofrequency ablation. J Gastroenterol Hepatol. 2014;29(1):157–64.CrossRefPubMedGoogle Scholar
  4. 4.
    Kudo A, Matsumura S, Ban D, et al. Does the preoperative alpha-fetoprotein predict the recurrence and mortality after hepatectomy for hepatocellular carcinoma without macrovascular invasion in patients with normal liver function? Hepatol Res. 2014;44(14):E437–46.CrossRefPubMedGoogle Scholar
  5. 5.
    Abdel-Hamid NM, Abouzied MM, Nazmy MH, Fawzy MA, Gerges AS. A suggested guiding panel of seromarkers for efficient discrimination between primary and secondary human hepatocarcinoma. Tumour Biol. 2015: [Epub ahead of print].Google Scholar
  6. 6.
    Zhong JH, Ke Y, Gong WF, et al. Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma. Ann Surg. 2014;260(2):329–40.CrossRefPubMedGoogle Scholar
  7. 7.
    Zhong JH, Wu FX, Li H. Hepatic resection associated with good survival for selected patients with multinodular hepatocellular carcinoma. Tumour Biol. 2014;35(9):8355–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Zhong JH, You XM, Lu SD, et al. Historical comparison of overall survival after hepatic resection for patients with large and/or multinodular hepatocellular carcinoma. Med (Baltimore). 2015;94(35), e1426.CrossRefGoogle Scholar
  9. 9.
    Trevisani F, D’Intino PE, Morselli-Labate AM, et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol. 2001;34(4):570–5.CrossRefPubMedGoogle Scholar
  10. 10.
    Omata M, Lesmana LA, Tateishi R, et al. Asian pacific association for the study of the liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010;4(2):439–74.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Kudo M, Izumi N, Kokudo N, et al. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis. 2011;29(3):339–64.CrossRefPubMedGoogle Scholar
  12. 12.
    Li C, Zhang Z, Zhang P, Liu J. Diagnostic accuracy of des-gamma-carboxy prothrombin versus alpha-fetoprotein for hepatocellular carcinoma: a systematic review. Hepatol Res. 2014;44(10):E11–25.CrossRefPubMedGoogle Scholar
  13. 13.
    Dai M, Chen X, Liu X, Peng Z, Meng J, Dai S. Diagnostic value of the combination of golgi protein 73 and alpha-fetoprotein in hepatocellular carcinoma: a meta-analysis. PLoS One. 2015;10(10):e0140067.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Zhou Y, Yin X, Ying J, Zhang B. Golgi protein 73 versus alpha-fetoprotein as a biomarker for hepatocellular carcinoma: a diagnostic meta-analysis. BMC Cancer. 2012;12:17.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Jia Z, Wang L, Liu C, Yu Z, Chai L, Zhao M. Evaluation of alpha-fetoprotein-L3 and Golgi protein 73 detection in diagnosis of hepatocellular carcinoma. Contemp Oncol (Pozn). 2014;18(3):192–6.Google Scholar
  16. 16.
    Zhao Y, Wang M, Cui C, et al. Significance of combined tests of serum golgi glycoprotein 73 and other biomarkers in diagnosis of small primary hepatocellular carcinoma. Cancer Biomark. 2015;15(5):677–83.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  1. 1.Gastroenterology DepartmentAffiliated Tumor Hospital of Guangxi Medical UniversityNanningChina
  2. 2.Hepatobiliary Surgery DepartmentAffiliated Tumor Hospital of Guangxi Medical UniversityNanningChina

Personalised recommendations